Clinical trials: Esrd
Renal Failure, End Stage Renal Disease
Comparison of Clinical Performance and Hemocompatibility of Dialyzers Applied During Post-dilution Online Hemodiafiltration
Comparison of the clinical performance and the hemocompatibility profile of different high-flux dialyzers, all applied during post-dilution online hemodiafiltration
- Trial name
- eMPORAIII (NCT04714281)
- Testing
- Dialyser
- Where
- 8 sites in Czechia, Germany and 1 more
- Volunteers
- 82 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Renal Failure, End Stage Renal Disease
Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
The main purpose of this study is to compare the Human Acellular Vessel (HAV) with arteriovenous fistula (AVF) when used for hemodialysis access
- Conditions
- Renal Failure, End Stage Renal Disease, Hemodialysis, Vascular Access
- Trial name
- NCT03183245
- Testing
- Human Acellular Vessel (HAV), Arteriovenous fistula (AVF), Hemodialysis
- Where
- 31 sites in United States
- Volunteers
- 242 people
- Sponsor
- Humacyte, Inc.
HIV Infections
A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)
An oral dose in healthy and renally impaired subjects to determine the drug effect for BMS-663068.
- Trial name
- NCT02674581
- Testing
- Oral BMS-663068 (pro-drug)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Chronic Kidney Disease, Atherosclerotic Cardiovascular Disease
A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.
The purpose of this study is to evaluate the safety, tolerability and the pharmacodynamics (PD) of AZD4144 following oral administration in participants with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney…
- Trial name
- NCT06675175
- Testing
- AZD4144
- Where
- 15 sites in United States, Bulgaria and 2 more
- Volunteers
- 29 people
- Sponsor
- AstraZeneca
Chronic Kidney Disease, Anemia
A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease.
The primary objective of this study is to compare the change in hemoglobin (Hb) from study start to the end of the study between the every 2 week and the every 4 week dosing regimens in patients with anemia of chronic kidney…
- Trial name
- NCT00212875
- Testing
- epoetin alfa
- Volunteers
- 267 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Cardiac Decompensation
Evaluate Heart Failure Patients With Specially Designed Patient Adherence and Monitoring Software on Standard Mobile Devices
This is planned as a feasibility study. The objective is to evaluate a specially designed patient adherence and monitoring software on standard mobile devices in remote monitoring of heart failure patients.
- Trial name
- REMOTE-HF-1 (NCT01430936)
- Where
- 5 sites in United States, India and 1 more
- Volunteers
- 51 people
- Sponsor
- Aventyn, Inc.
Kidney Disease, Chronic Kidney Disease
Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease
The purpose of this study is to determine whether darbepoetin alfa manufactured by the current "roller bottle" technology and darbepoetin alfa manufactured by a serum free process have a comparable safety profile.
- Trial name
- NCT00093977
- Testing
- darbepoetin alfa SF
- Volunteers
- 1,100 people
- Sponsor
- Amgen
Healthy, Renal Impairment
A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems
This study is open to adults aged between 18 and 80 years of age with a body mass index (BMI) of 20 to 40 kg/m2. People with or without kidney problems can take part in the study.
- Trial name
- NCT06352411
- Testing
- BI 456906
- Where
- 2 sites in Germany
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Hepatorenal Syndrome
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
This study is designed to evaluate the efficacy and safety of intravenous terlipressin versus placebo for the treatment of type 1 hepatorenal syndrome (HRS) in participants receiving standard of care albumin therapy.
- Trial name
- NCT01143246
- Testing
- Terlipressin
- Where
- 73 sites in United States, Canada
- Volunteers
- 196 people
- Sponsor
- Mallinckrodt
Chronic Kidney Diseases, Renal Disease
Evaluation of Renastep
Evaluation of Renastep is a 28-day long, prospective nutritional study that will recruit 15 patients aged between 3 and 18 years of age with Chronic Kidney Disease.
- Trial name
- Renastep (NCT03602937)
- Testing
- Renastep
- Where
- 3 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Vitaflo International, Ltd
End Stage Renal Disease
Preliminary Safety of The TRUE Vascular Graft for Hemodialysis Access (TRUE HD I Study)
Prospective, nonrandomized, single-arm, single-center, open-label, first-in-human clinical study in subjects with end-stage renal disease (ESRD) and not candidates for an autogenous fistula creation.
- Trial name
- NCT04905511
- Testing
- natural human collagen arteriovenous graft for hemodialysis access
- Where
- Paraguay
- Volunteers
- 10 people
- Sponsor
- Vascudyne, Inc.
Renal Impairment
Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment
To investigate the pharmacokinetics (PK) of rifabutin in subjects with renal impairment after single intravenous (IV) infusion of BV100
- Trial name
- NCT05086107
- Testing
- BV100
- Where
- Hungary
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- BioVersys AG
Hyperphosphatemia, Chronic Kidney Disease
Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients
This study will compare placebo to 4 different doses of SBR759 to assess the phosphate lowering efficacy in dialysis patients.
- Trial name
- SBR759 (NCT01069692)
- Testing
- SBR759A
- Where
- 9 sites in Belgium, Italy
- Volunteers
- 115 people
- Sponsor
- Novartis
End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD)
Clinical Effectiveness and Resource Use in End-Stage Renal Disease Patients: Remote Patient Monitoring Across Dialysis Modalities
This is a multicenter, prospective, observational real-world study designed to evaluate clinical effectiveness, quality of life, and healthcare resource utilization in patients with end-stage renal disease (ESRD) initiating…
- Trial name
- NCT07781124
- Testing
- Remote patient monitoring-automated peritoneal (RPM-APD), Manual peritoneal dialysis (PD) cohort, Maintenance hemodialysis (HD)
- Where
- 20 sites in China
- Volunteers
- 750 people
- Sponsor
- Vantive Health LLC
Chronic Kidney Disease
A Phase II Clinical Trial of the Safety and Efficacy of SAL0120 in Patients With Chronic Kidney Disease (CKD)
This study is a multicenter, randomized, double-blind, placebo-controlled, parallel-design clinical trial designed to investigate the efficacy and safety of different doses of sal0120 tablets in patients with CKD.
- Trial name
- NCT07716618
- Testing
- SAL0120 1mg, SAL0120 2mg, SAL0120 4mg
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Chronic Kidney Disease Stage 5
Study to Assess Pegloticase (KRYSTEXXA®) in Patients on Hemodialysis
This is a Phase 1 single dose study conducted to evaluate the PK and PD of pegloticase administered to hemodialysis patients. A single dose of pegloticase will be administered intravenously to male or female hemodialysis patients…
- Trial name
- NCT01739660
- Testing
- Pegloticase
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Savient Pharmaceuticals
Anemia, End Stage Renal Disease (ESRD)
Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis
This study was conducted to explore a new therapy for anemia in participants with end stage renal disease (ESRD) on dialysis. Anemia is a reduced number of red blood cells or hemoglobin.
- Trial name
- Pyrenees (NCT02278341)
- Testing
- Roxadustat, Epoetin alfa, Darbepoetin alfa
- Where
- 143 sites in Belgium, Bulgaria and 15 more
- Volunteers
- 838 people
- Sponsor
- Astellas Pharma Europe B.V.
Anemia, Mortality
Impact of Adherence to Anemia Management Policy on Repeat Hospitalization in End Stage Renal Disease (ESRD)
The investigators hypothesize that the post-hospitalized patient status is characterized by subacute and reversible metabolic and hematological changes that, if addressed and treated in a timely manner, would result in a reduced…
- Trial name
- NCT01017627
- Testing
- Early anemia diagnosis and treatment, No change from normal routine
- Where
- 42 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Fresenius Medical Care North America
Chronic Kidney Disease, Renal Failure Chronic Requiring Hemodialysis
Specific Enteral Nutrition in Malnourished, Dialysis Patients With Chronic Kidney Disease. Efficacy, Safety, Quality of Life
The objective of this unblinded study is to assess the nutritional effects of a 12 weeks administration of the specific enteral nutrition (SEN) RealDiet®Renal pockets, as well as the impact on the patients' quality of life.
- Conditions
- Chronic Kidney Disease, Renal Failure Chronic Requiring Hemodialysis, Severe Malnutrition, Tolerance
- Trial name
- AL-EN-PHED (NCT01946841)
- Testing
- RealDiet®Renal
- Where
- France
- Sponsor
- Lactalis
Renal Failure, End Stage Renal Disease
Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis
The main purpose of this study is to compare the Human Acellular Vessel (HAV) with ePTFE grafts when used for hemodialysis access.
- Conditions
- Renal Failure, End Stage Renal Disease, Hemodialysis, Vascular Access
- Trial name
- NCT02644941
- Testing
- Human Acellular Vessel (HAV), ePTFE graft
- Where
- 38 sites in United States, Germany and 4 more
- Volunteers
- 355 people
- Sponsor
- Humacyte, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.